CRH Medical Corp. | StockChase
80
CRH Medical Corp. (CRH-T)

Last Price Recorded: $2.3200 on 2017-11-17

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert

2017-04-11

PARTIAL BUY
CRH Medical Corp. (CRH-T)

He likes this. A bit of a rollup. They are buying portions of medical practices in the US, and then are installing anaesthesiologists to do anaesthetic services. The valuation is running up a bit, but if you are looking at Enterprise Value to a bit of multiple, it is about 16X. Still a bit pricey, but nothing too crazy. He likes that they are offering liquidity to doctors, who are starting to age and want to get some cash out of the business. Good insider ownership. Worth owning, but you might want to average into it.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research

Price: $12.030
Owned: No

2017-08-02

COMMENT
CRH Medical Corp. (CRH-T)

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research

Price: $4.600
Owned: Unknown

2017-11-14

DON'T BUY
CRH Medical Corp. (CRH-T)

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research

Price: $1.920
Owned: Unknown

2015-10-16

COMMENT
CRH Medical Corp. (CRH-T)

Treatment of haemorrhoids. Stock is declining because earnings estimates have been shaved by 15% in the last 90 days. The advantage is that no surgery is required compared to other methods. Trading at 18X PE for 2016. Analysts are expecting earnings to grow from $0.10-$0.22, but estimates have been shaved 15% in the last 90 days, which is why the stock has been drifting off.

biotechnology/pharmaceutical
Robert McWhirter

President, Selective Asset Management

Price: $3.610
Owned: No

2016-02-08

BUY
CRH Medical Corp. (CRH-T)

They have gone through some lumps.  Analysts are expecting earnings growth of 69%.  It looks like they finally turned the company around.  14 times PE. 

biotechnology/pharmaceutical
Robert McWhirter

President, Selective Asset Management

Price: $3.460
Owned: Unknown

2017-04-26

COMMENT
CRH Medical Corp. (CRH-T)

Ranks 222 out of 723 stocks in his model. If putting new money to work, you would typically look for something higher up in the rank. Currently trading at $9.12, and the overall earnings estimates for 2017 is $.28, giving a reasonable PE multiple. ROE of 25% looks attractive. Next year’s earnings growth is expected to be 21%, against a 28 PE, giving a PE to growth next year of 1.3X. It looks a bit expensive.

biotechnology/pharmaceutical
Robert McWhirter

President, Selective Asset Management

Price: $8.990
Owned: Unknown

2015-02-23

BUY
CRH Medical Corp. (CRH-T)

Hemorrhoid business.  Acquisition they made is quite accretive.  People are just becoming aware of this story.  A high margin business.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.800
Owned: Unknown

2015-06-19

TOP PICK
CRH Medical Corp. (CRH-T)

In terms of management, they are a little more conservative than some of the others. They were in the haemorrhoid business, but do a lot of anaesthesia for colonoscopies, etc, and that business has been growing very rapidly. Made a transformative acquisition at the end of last year, and are on the cusp of probably making a couple more over the next 6 months or so. Recent quarter was very strong and expects Q2 to be strong as well.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $4.110
Owned: Yes

2015-09-28

TOP PICK
CRH Medical Corp. (CRH-T)

Healthcare space.  The management team’s last company sold at a great multiple.  They can get synergies and revenues up.  It sold off here.  It will be a long term hold for him.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $4.210
Owned: Yes

2016-01-08

BUY
CRH Medical Corp. (CRH-T)

He likes this. It has been fairly strong over the last couple of weeks. Good management team. The cash flow from operations should rise quite a bit this year. Probably trading at around 8X 2016 EBITDA. If you are going to own something in this space, this is a go to name.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.940
Owned: Yes

2016-05-12

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(Top Pick Jun 19/15, Down 9.00%) They have done a good job.  They don’t need to raise prices.  9 times earnings.  They are probably looking for acquisitions.  The balance sheet looks good.  A premier small cap name so he continues to hold it.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.730
Owned: Yes

2016-07-20

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(A Top Pick Sept 28/15. Up 23.28%.) Not sure who is buying this, but somebody is buying quite a bit of stock. Most healthcare stocks in Canada have not done well, but this one has. He really likes management, which underpromises and overdelivers. Recently made a few acquisitions which should be accretive. Only trading at about 8.5X EBITDA with very good growth over the next couple of years.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $5.120
Owned: Yes

2016-09-29

HOLD
CRH Medical Corp. (CRH-T)

He really likes the management team.  He continues to hold it although the whole healthcare sector has been under scrutiny.  Their earnings have grown as they made tuck-in acquisitions.  They recently did some marketing.  Over the next couple of years earnings estimates should go up.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $5.110
Owned: Yes

2016-12-20

BUY
CRH Medical Corp. (CRH-T)

It is a buy or a hold.  He is one of the largest holders.  This has been a top pick of his.  It is a health care company, the top performing one in Canada this year.  They did a very good job at increasing their earnings.  Last quarter the stock took off.  A lot more small cap managers are looking at it now.  He likes the management team from a previous company.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $7.060
Owned: Yes

2017-02-28

HOLD
CRH Medical Corp. (CRH-T)

Involved with gastrointestinal, and they work with anesthesia to provide for colonoscopies, etc. They’ve been trying to consolidate the market. Just reported a blowout quarter and the stock moved up quite a bit. Management has done a great job of under promising and over delivering.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $9.190
Owned: Yes

Showing 1 to 15 of 80 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.